Neoplasia/BPH

	High-sensitivity Raman spectroscopy for prostate cancer detection and tissue extraction guidance. Biomed Opt Express Dooley MJ, Li H, Low I, Christie ML, Pokorny MR, Araquel-Lacamiento A, Porter A, Zargar-Shoshtari K, Aguergaray C. PMID: 42460332 [PubMed]
	Clinical efficacy analysis of acupuncture combined with anti-tumor necrosis factor treatment for spleen and kidney yang deficiency type ulcerative colitis. Front Med (Lausanne) Qin P, Luo Y, Yao Y, Zhu N, Yi W. PMID: 42460073 [PubMed]
	MicroRNA-based diagnosis and therapy in prostate cancer. 3 Biotech Nguyen TA, Le TT, Duong KT, Nguyen AH, Quang MT. PMID: 42459410 [PubMed]
	Androgen receptor signaling organizes ferroptosis escape in castration-resistant prostate cancer: a threshold-based model for therapeutic timing. Front Oncol Wang C, Lv J, Wu J, Wang S, Song S. PMID: 42459323 [PubMed]
	Identification of key genes potentially associated with bladder cancer development by common plasticizers: an integrated transcriptomics and network toxicology study. Front Oncol Zhang Q, Xu K, Chen Z, Li Z, Zhao D. PMID: 42459315 [PubMed]
	External validation of the P-Score in the prospective, pre-biopsy DEPROMP cohort: integrated mpMRI and PSMA PET/CT risk stratification for prostate cancer detection. Eur J Nucl Med Mol Imaging Schmidt CJ, Gaertner FC, Kreppel B, Essler M, Luetkens JA, Attenberger U, Anspach M, Ohlmann CH, Bernhardt M, Kristiansen G, Hauser S, Ellinger J, Ritter M, Krausewitz P. PMID: 42458057 [PubMed - as supplied by publisher]
	Long-term outcomes of real-time TRUS-guided HDR brachytherapy monotherapy for low and favorable intermediate-risk prostate cancer and predictive value of PSA nadir. Brachytherapy Gaztañaga M, Escribano C, Montero B, de Areba J, Martínez DF, Galante I, Serrano-Garcia I, Vázquez MG. PMID: 42457607 [PubMed - as supplied by publisher]
	ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT. Eur Urol Focus Franz J, Brumberg J, Mix M, Meyer PT, Herrmann K, Gratzke C, Sigle A. PMID: 42457482 [PubMed - as supplied by publisher]
	Novel BCG Combination or Modified BCG Regimens in BCG-NaÃ¯ve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus Pattou M, Rouprêt M, Kamat A, Boorjian SA, Gontero P, Shariat SF, D'Andrea D. PMID: 42457481 [PubMed - as supplied by publisher]
	Re: [177Lu]-PSMA-617-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE): An Open-label, Randomised, Phase 2 Study. Eur Urol Belliveau C, Kishan AU, Calais J, Plouznikoff N, Ménard C. PMID: 42457458 [PubMed - as supplied by publisher]
	Re: Testosterone Treatment in Prostate Cancer Survivors with Hypogonadism: A Randomized Clinical Trial. Eur Urol O'Callaghan ME, Selth L, Wittert G. PMID: 42457457 [PubMed - as supplied by publisher]
	EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol Cornford P, van den Bergh RCN, Briers E, Chiu P, Eberli D, Epure A, Farolfi A, Fonteyne V, Gandaglia G, Gillessen S, Grivas N, Henry AM, van Leenders GJLH, Espinos EL, Matsen B, Oldenburg J, van Oort IM, Oprea-Lager DE, Roberts MJ, Rouvière O, Sachdeva A, Santis M, Schoots IG, Smith EJ, Stranne J, Wiegel T, Tilki D. PMID: 42457454 [PubMed - as supplied by publisher]
	Diagnostic performance of artificial intelligence based on PET/CT for lymph node involvement in prostate cancer: A systematic review and meta-analysis. Int J Med Inform Song D, Zhao Z, Chen K. PMID: 42456599 [PubMed - as supplied by publisher]
	Alcohol consumption increased the risk of prostate cancer: A Finnish pooled population-based cohort study. Eur J Cancer Tarkiainen L, Lappi-Heikkinen S, Seppä K, Ryynänen H, Laaksonen MA, Knekt P, Männistö S, Härkänen T, Jousilahti P, Koskinen S, Eriksson JG, Heinävaara S, Rahkonen O, Pitkäniemi J, METCA Study Group. PMID: 42456540 [PubMed - as supplied by publisher]
	Focal Therapy for Prostate Cancer: A Treatment Option Reserved for the Ideal Candi-date? Int Braz J Urol Cignoli D, de Oliveira JPB, Rodriguez-Serrano A, Lopez D, Stabile A, Salonia A, Briganti A, Montorsi F, La Croce G, Catellani M, Barzaghi P, Roscigno M, Da Pozzo LF, Rojas YA, Brambila JCG, Lanz C, Barret E, Macek P, Cathelineau X, Rodriguez-Sanchez L. PMID: 42455608 [PubMed - indexed for MEDLINE]
	Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer. JAMA Netw Open Peyrottes A, Baboudjian M, Long-Depaquit T, Rouprêt M, Roumeguere T, Peltier A, Ploussard G, Diamand R, iTNM Consortium. PMID: 42455568 [PubMed - indexed for MEDLINE]
	Burden of bladder cancer in China from 1990 to 2023: temporal trends, modifiable risk factors, and implications for prevention. Int J Clin Oncol Bai Z, Wang S, Wang H, Liu Z, Hou S, Huang G, Hou Y. PMID: 42455460 [PubMed - as supplied by publisher]
	Immunotherapeutic strategies for castration-resistant prostate cancer: A systematic review of mechanisms, clinical advances and emerging approaches. Mol Biol Rep Xu Z, Xia Z, Li J, Yuan S, Zhao L, Wang X. PMID: 42455319 [PubMed - indexed for MEDLINE]
	Optimal Imaging Strategies After Negative PSMA PET/CT Results in Patients With Prostate Cancer Biochemical Recurrence: AJR Expert Panel Narrative Review. AJR Am J Roentgenol Choi WP, Almaguel FG, Franquet-Elia E, Ghai S, Gorin MA, Repka M, Hicks RJ, Turkbey B, Umutlu L, Rowe SP, Behr SC. PMID: 42455032 [PubMed - as supplied by publisher]
	A comprehensive study of intratumor bacteria in clear-cell renal cell carcinoma identifies Cutibacterium acnes as a protector via suppression of macrophage M2 polarization. mSystems Li Y, Zhang D, Tan L, Xu J, Sun Y, Zhang R, Cheng Y, Li Y-x, Guo T, Jiang H, Zhai W, Feng C. PMID: 42454938 [PubMed - as supplied by publisher]

Articles 1 - 20 / 189795

Page 1 of 9490



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy